Mackie Research Capital analyst Andre Uddin says Immunovaccine's (TSX:IMV) interim results for its phase 1b clinical study of its novel
T-cell-activating immuno-oncology candidate, DPX-Survivac, are "what you want to see for efficacy".
Knight Therapeutics' (TSX:GUD) fourth quarter results bested his expectations, but Mackie Research Capital analyst
Andre Uddin isn't quite ready to call the stock a buy yet.
This morning, Knight reported its fourth quarter and fiscal 2016 results. In the fourth quarter, the company earned $7.9-million
on revenue of $1.8-million, a topline that was up from the $300,000 it reported in the same period last year
A better than expected quarter has Mackie Research Capital analyst Andre Uddin feeling
good about Theratechnologies' (TSX:TH) prospects.
This morning, Theratechnologies reported its Q4 and fiscal 2016 results. In the
fourth quarter, the company posted EBITDA of $2.81-million on revenue of $10.37-million, a
topline that was up 15.2 per cent over the same period a year prior.
Mackie Research recently released a research report entitled "Under-leveraged, Undervalued Growth Stocks with Momentum
The stocks Mackie selected each have market capitalizations of less than $100-million (Canadian), and may
not be suitable for more risk-averse investors. Having said that, here are three oil and gas stocks that Mackie Research
believes have strong potential for solid gains.
Some good news from Syncordia Technologies (TSXV:SYN) is confirming Mackie Research Capital analyst Nikhil
Thadani's bullish take on the stock, says the analyst.
Yesterday, Syncordia announced that its wholly owned subsidiary, Health Services Integration, was "pushing
through inititiatives" that will add over $1-million annually to the bottom line, annually. The company also
said that Billing Solutions, which it owns 80 per cent of, was in the process of signing contracts that would
add $300,000 in annualized EBITDA, and that its wholly owned subsidiary Paragon Billing would also be adding
$300,000 in EBITDA annually, from new contracts.
The long awaited listing of Jackpotjoy shares in the United Kingdom may begin to tighten the valuation gap between Intertain Group (TSX:IT) and its more expensive peers, says Mackie Research Capital analyst Nikhil Thadani… Read More